Cover -- Title page -- Copyright page -- Contents -- List of Contributors -- Preface -- 1: Dermatology and Oncology -- 1: Epidemiology and Burden of Disease -- Introduction -- Dermatologic health in cancer patients and survivors -- Financial burden -- Health-related quality of life -- Dosing of chemotherapy -- Conclusions -- References -- Appendix 1.1 Anticancer agents and associated adverse events affecting the skin, mucosa, hair, and nails. Based on data from Litt JZ, 2009 [8]. -- 2: The History of Supportive Oncodermatology -- Evolution of anticancer therapeutics -- Spectrum of dermatologic adverse events stemming from conventional cytotoxic chemotherapy agents -- Radiation and surgery-induced mucocutaneous toxicities -- Mucocutaneous toxicities induced by novel targeted agents -- Emergence of supportive oncodermatology and future directions -- References -- 3: Structure and Function of the Integumentary System and the Dermatology Lexicon -- Introduction -- Skin -- Epidermis -- Dermal-epidermal junction -- Dermis -- Vasculature -- Nerves -- Subcutaneous tissue -- Appendages -- Eccrine sweat glands -- Apocrine sweat glands -- Sebaceous glands -- Hair -- Nails -- Morphology -- Raised lesions -- Papule -- Plaque -- Nodule -- Cyst -- Wheal -- Depressed lesions -- Erosion -- Ulcer -- Atrophy -- Poikiloderma -- Flat lesions -- Macule -- Patch -- Sclerosis -- Erythema -- Erythroderma -- Fluid-filled lesions -- Vesicle and bulla -- Pustule -- Furuncle -- Abscess -- Surface changes -- Scale -- Crust -- Eschar -- Purpura and vascular lesions -- Purpura -- Infarct -- Shape, configuration, arrangement, and distribution of lesions -- Conclusions -- 4: Types of Dermatologic Reactions -- Exanthematous eruptions -- Urticarial eruptions -- Lichenoid eruptions -- Acneiform eruptions -- Pustular eruptions (acute generalized exanthematous pustulosis).

Bullous eruptions -- Drug-induced vasculitis -- Erythroderma -- Approach to patients with suspected drug eruption -- Step 1: Recognizing the morphology -- Step 2: Associated symptoms and systemic involvement -- Step 3: Histopathologic assessment -- Step 4: Determining the offending drug -- Conclusions -- References -- 5: Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0 -- Common Terminology Criteria for Adverse Events -- CTCAE grade scale -- Attribution -- Changes in CTCAE V4.0 -- Refined grading to correlate with clinical management -- Alopecia -- Rash acneiform -- Skin hyperpigmentation -- Split of embedded terms -- Rash maculopapular -- Erythroderma -- Bullous dermatitis -- Nail discoloration, nail ridging, and nail loss -- New adverse events -- Hypertrichosis -- Hypohidrosis -- Lipohypertrophy -- Periorbital edema -- Moved to different SOC -- Papulopustular rash -- Rash pustular -- Paronychia -- CTCAE vs. MESTT -- Conclusions -- References -- 6: Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology -- Psychosocial distress -- Distress among dermatologic samples -- Dermatologic AEs from cancer treatment -- Risk factors for distress -- Clinical management of distress -- Measuring distress and health-related quality of life in dermatologic oncology -- Psychosocial interventions in oncodermatology -- Conclusions -- References -- 7: Dermatopathology -- Introduction -- Mucocutaneous neoplasms -- Solar (actinic) keratosis -- Squamous cell carcinoma -- Melanocytic tumors -- Inflammatory dermatoses -- Interface (lichenoid) dermatitis -- Spongiotic dermatitis -- Superficial or superficial and deep perivascular lymphohistiocytic inflammation -- Suppurative and granulomatous dermatitis -- Conclusions -- References.

2: Cancer-Related Dermatologic Disorders -- 8: Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses -- Paraneoplastic disorders -- Skin changes from hormone-secreting tumors -- Ectopic ACTH-producing tumors -- Proliferative and inflammatory paraneoplastic dermatoses -- Inherited syndromes with increased cancer risk and skin effects -- Muir-Torre syndrome -- Gardner syndrome -- Cowden syndrome -- Peutz-Jeghers syndrome -- Birt-Hogg-Dubé -- Howel-Evans syndrome -- Hereditary leiomyomatosis/renal cell cancer syndrome -- Environmental carcinogens with increased cancer risk and skin effects -- Arsenic -- Vinyl chloride -- Ionizing radiation -- References -- 3: Dermatologic Conditions During Cancer Therapy -- 9: Oral Mucosal Complications of Cancer Therapy -- Introduction -- Mucosal injury attributable to cytotoxic therapy -- Clinical features and course of mucositis -- Mucositis scoring -- Clinician-based scoring -- Toxicity description and assessment -- Patient management scales -- Research-directed scales -- Variability between mucositis scales -- Patient-reported instruments to assess mucositis severity -- Minimizing inter-observer variability in mucositis assessment -- Impact of mucositis -- Pathobiology of mucositis -- Signal amplification -- Risk factors for mucositis -- The oral environment and mucositis -- Status of the development of therapies for mucositis -- Mucosal changes associated with targeted therapies -- Mucosal injury associated with mTOR inhibitors -- Small molecules and antibodies -- Oral manifestations of graft versus host disease -- Conclusions -- References -- 10: Hair Disorders Associated with Anticancer Agents -- Introduction -- Basic hair anatomy and function -- Types of chemotherapy-induced hair loss/alopecia -- Telogen effluvium -- Anagen effluvium -- Abnormal hair growth.

Permanent chemotherapy-induced alopecia -- Radiation-induced alopecia -- Grading scales utilized for determining degree of hair loss or regrowth -- Potential treatments for chemotherapy-induced alopecia -- Prevention of hair loss -- Acceleration of regrowth after chemotherapy -- Conclusions -- References -- 11: Nail Abnormalities in Oncology Practice -- Introduction -- Drugs -- Classic cytotoxic drugs -- Epidermal growth factor receptor inhibitors -- Symptoms -- Nail matrix and nail plate alterations -- Nail fold involvement -- Nail bed involvement -- Digit tip xerosis -- Classification -- Treatment -- Prevention -- Conclusions -- References -- 12: Pruritus -- Introduction -- Cutaneous diseases -- Systemic and psychiatric diseases -- Malignancy -- Therapy -- Clinical findings -- Visual analog scale for pruritus -- Management -- General principles -- Topical treatments -- Systemic treatments -- Physical treatments -- Phototherapy -- Bio-behavioral therapy -- Conclusions -- References -- 13: Management Options for Hot Flashes in Cancer Patients -- Introduction -- Grading of hot flashes -- Treatment of hot flashes -- Pharmacologic interventions -- Nonpharmacologic interventions -- Behavioral therapies -- Physical measures -- Conclusions and recommendations -- References -- 4: Skin Toxicities to Chemotherapy -- 14: Alkylating Agents -- Introduction -- Nitrogen mustards -- Mustargen (mechlorethamine) -- Cyclophosphamide -- Ifosfamide -- Melphalan -- Chlorambucil -- Aziridines and epoxides -- ThioTEPA -- Mitomycin C -- Alkyl sulfonates -- Busulfan -- Nitrosoureas -- Carmustine (bischloroethylnitrosourea) -- Streptozocin -- Hydrazines and triazine derivatives -- Procarbazine -- Dacarbazine -- Temozolomide -- Hydroxurea -- References -- 15: Antimetabolite Reactions -- Introduction -- Methotrexate -- Pemetrexed -- Capecitabine -- Cytarabine -- Gemcitabine.

Mercaptopurine -- Thioguanine -- Fludarabine -- Cladribine -- References -- 16: Topoisomerase-Interacting Agents -- Introduction -- Topoisomerase I inhibitors -- Irinotecan and topotecan -- Topoisomerase II inhibitors -- Anthracyclines: Doxorubicin, liposomal doxorubicin, epirubicin and idarubicin -- Etoposide and teniposide -- Mitoxantrone -- Alopecia -- Hand-foot syndrome -- Hyperpigmentation -- Intertrigo -- Nail changes -- Extravasation of topoisomerase inhibitors -- Stevens-Johnson syndrome -- Mucositis -- Radiation recall -- References -- 17: Epidermal Growth Factor Receptor Inhibitor Reactions -- Introduction -- Epidermal growth factor receptor inhibitors -- Dermatologic adverse events of EGFRIs -- Papulopustular (acneiform) rash -- Xerosis and pruritus -- Hyperpigmentation -- Telangiectasias -- Mucosal toxicities -- Hair alterations -- Nail and periungual involvement -- Interaction of EGFRIs with conventional cytotoxic chemotherapy and radiotherapy -- Conclusions -- References -- 18: Small Molecule Multikinase Inhibitors -- Introduction -- Kit, PDGFR and bcr-abl inhibitors: imatinib, nilotinib, dasatinib -- Drugs, indications, and mechanisms of action -- Antiangiogenic agents: sorafenib, sunitinib axitinib, regorafenib, and pazopanib -- Hand-foot skin reaction -- Subungual splinter hemorrhages -- Erythematous rashes -- Hair modifications -- Xerosis -- Genital involvement -- Mucositis -- AEs specifically related to sunitinib -- AEs related specifically to sorafenib -- mTOR inhibitors: everolimus and temsirolimus -- Drugs and mechanisms of action -- Skin manifestations -- Conclusions -- References -- 19: Antimicrotubule Agents -- Introduction -- Taxanes -- Clinical features -- Treatment of choice and prognosis -- Vinca alkaloids -- Clinical features -- Treatment of choice and prognosis -- Estramustine phosphate sodium -- References.

20: Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids.